Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS). The randomized, double-blind study ...
Tenax Therapeutics (TENX) is in a very good position as far as its drug development plan goes for its drug levosimendan. That's because it is already in the process of running the ongoing phase 3 ...
Prothena Corporation plc (PRTA) just the other week announced data from its phase 3 AFFIRM-AL clinical trial using birtamimab for the treatment of patients with AL amyloidosis. The really bad news ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results